The 18 kDa isoform of basic fibroblast growth factor is sufficient to stimulate human melanoma growth and angiogenesis

Melanoma Research

Volumn 17, Issue 3, 2007, Pages 155-168

  Fontijn, Dennis ^a   Duyndam, Monique C A ^a   Beliën, Jeroen A M ^a   Gallegoz Ruiz, Marielle I ^a   Pinedo, Herbert M ^a   Boven, Epie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Basic fibroblast growth factor proteins; Cutaneous melanoma

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; ISOPROTEIN;

ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER GROWTH; CELL STIMULATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR CLONING; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN VARIANT; SKIN CARCINOGENESIS; SKIN CARCINOMA; TUMOR VASCULARIZATION; XENOGRAFT;

ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR WEIGHT; NEOVASCULARIZATION, PATHOLOGIC; PARACRINE COMMUNICATION; PHOSPHORYLATION; RECOMBINANT PROTEINS; RNA, MESSENGER; TRANSFECTION;

EID: 34249035047     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328184451e     Document Type: Article

References (47)

1. Rodeck U. Growth factor independence and growth regulatory pathways in human melanoma development. Cancer Metastasis Rev 1993; 12:19-26.
2. Halaban R. Growth factors and melanomas. Cancer Metastasis Rev 1996; 23:673-681.
3. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000; 12:547-554.
4. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997; 18:26-45.
5. Halaban R, Langdon R, Birchall N, Cuono C, Baird A, Scott G, et al. Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes. J Cell Biol 1988; 107:1611-1619.
6. Dotto GP, Moellmann G, Ghosh S, Edwards M, Halaban R. Transformation of murine melanocytes by basic fibroblast growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment. J Cell Biol 1989; 109:3115-3128.
7. Halaban R, Kwon BS, Ghosh S, Delli Bovi P, Baird A. bFGF as an autocrine growth factor for human melanomas. Oncogene Res 1988; 3:177-186.
8. Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 1989; 8:3685-3691.
9. Becker D, Lee PL, Rodeck U, Herlyn M. Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene 1992; 7:2303-2313.
10. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997; 3:887-893.
11. Ackerman J, Beermann F. The fibroblast growth factor-2 is not essential for melanoma formation in a transgenic mouse model. Pigment Cell Res 2005; 18:315-319.
12. Foletti A, Ackermann J, Schmidt A, Hummier E, Beermann F. Absence of fibroblast growth factor-2 does not prevent tumor formation originating from the RPE. Oncogene 2002; 14:1841-1847.
13. Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S, et al. Fibroblast growth factor 2 promotes tumor progression in an autochtonous mouse model of prostate cancer. Cancer Res 2003; 63:5754-5760.
14. Jaye M, Schlessinger J, Dionne CA. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta 1992; 1135:185-199.
15. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64:841-848.
16. Halaban R, Funasaka Y, Lee P, Rubin J, Ron D, Birnbaum D. Fibroblast growth factors in normal and malignant melanocytes. Ann N Y Acad Sci 1991; 638:232-243.
17. Easty DJ, Ganz SE, Farr CJ, Lai C, Herlyn M, Bennett DC. Novel and known protein tyrosine kinases and their abnormal expression in human melanoma. J Invest Dermatol 1993; 101:679-684.
18. Florkiewicz RZ, Sommer A. Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. Proc Natl Acad Sci U S A 1989; 86:3978-3981.
19. Prats H, Kaghad M, Prats AC, Klagsbrun M, Lelias JM, Liauzun P, et al. High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. Proc Natl Acad Sci U S A 1989; 86:1836-1840.
20. Arnaud E, Touriol C, Boutonnet C, Gensac MC, Vagner S, Prats H, et al. A new 34-kilodalton isoform of human fibroblast growth factor 2 is cap dependently synthesized by using a non-AUG start codon and behaves as a survival factor. Mol Cell Biol 1999; 19:505-514.
21. Bugler B, Amalric F, Prats H. Alternative initiation of translation determines cytoplasmic or nuclear localization of basic fibroblast growth factor. Mol Cell Biol 1991; 11:573-577.
22. Florkiewicz RZ, Baird A, Gonzalez AM. Multiple forms of bFGF: differential nuclear and cell surface localization. Growth Factors 1991; 4:265-275.
23. Quarto N, Finger FP, Rifkin DB. The NH2-terminal extension of high molecular weight bFGF is a nuclear targeting signal. J Cell Physiol 1991; 147:311-318.
24. Renko M, Quarto N, Morimoto T, Rifkin DB. Nuclear and cytoplasmic localization of different basic fibroblast growth factor species. J Cell Physiol 1990; 144:108-114.
25. Westphal JR, Van 't Hullenaar RG, Van der Laak JA, Cornelissen IM, Schalkwijk LJ, van Muijen GN, et al. Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. Br J Cancer 1997; 76:561-570.
26. Van Muijen GN, Cornelissen LM, Jansen CF, Figdor CG, Johnson JP, Brocker EB, et al. Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin Exp Metastasis 1991; 9:259-272.
27. Lockshin A, Giovanella BC, De Ipolyi PD,Williams LJ, Mendoza JT, Yim SO, et al. Exceptional lethality for nude mice of cells derived from a primary human melanoma. Cancer Res 1985; 45:345-350.
28. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 7:248-254.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
30. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998; 77:1-10.
31. Beliën JA, Somi S, De Jong JS, Van Diest PJ, Baak JP. Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer. J Clin Pathol 1999; 52:184-192.
32. Quarto N, Talarico D, Florkiewicz R, Rifkin DB. Selective expression of high molecular weight basic fibroblast growth factor confers a unique phenotype to NIH 3T3 cells. Cell Regul 1991; 2:699-708.
33. Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S, Schmiegel W. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res 2001; 61:7282-7290.
34. Joy A, Moffett J, Neary K, Mordechai E, Stachowiak EK, Coons S, et al. Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells. Oncogene 1997; 14:171-183.
35. Bikfalvi A, Klein S, Pintucci G, Quarto N, Mignatti P, Rifkin DB. Differential modulation of cell phenotype by different molecular weight forms of basic fibroblast growth factor: possible intracellular signaling by the high molecular weight forms. J Cell Biol 1995; 129:233-243.
36. Arese M, Chen Y, Florkiewicz RZ, Gualandris A, Shen B, Rifkin DB. Nuclear activities of basic fibroblast growth factor: potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals. Mol Biol Cell 1999; 10:1429-1444.
37. Trudel C, Faure-Desire V, Florkiewicz RZ, Baird A. Translocation of FGF2 to the cell surface without release into conditioned media. J Cell Physiol 2000; 185:260-268.
38. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohno K, et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996; 271:28220-28228.
39. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141:1659-1673.
40. Claffey KP, Abrams K, Shih SC, Brown LF, Mullen A, Keough M. Fibroblast growth factor 2 activation of stromal cell vascular endothelial growth factor expression and angiogenesis. Lab Invest 2001; 81:61-75.
41. Czubayko F, Liaudet-Coopman ED, Aigner A, Tuveson AT, Berchem GJ, Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 1997; 3:1137-1140.
42. Aigner A, Butscheid M, Kunkel P, Krause E, Lamszus K, Wellstein A, et al. An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer 2001; 92:510-517.
43. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003; 63:756-759.
44. Debiais F, Lefevre G, Lemonnier J, Le Mee S, Lasmoles F, Mascarelli F, et al. Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent, -beta-catenin-independent signaling pathway. Exp Cell Res 2004; 297:235-246.
45. Kozawa O, Tokuda H, Matsuno H, Uematsu T. Involvement of p38 mitogen-activated protein kinase in basic fibroblast growth factor-induced interleukin-6 synthesis in osteoblasts. J Cell Biochem 1999; 74:479-485.
46. Tessner TG, Muhale F, Schloemann S, Cohn SM, Morrison A, Stenson WF. Basic fibroblast growth factor upregulates cyclooxygenase-2 in I407 cells through p38MAP kinase. Am J Physiol Gastrointest Liver Physiol 2003; 284:G269-G279.
47. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-2147.